The international surgical journal with global reach

A novel immune modulator for patients with necrotizing soft tissue infections (NSTI). Results of a multicenter, phase 3 randomized controlled trial of Reltecimod (AB 103). Ann Surg 2020; 272: 469-478.

Published: 15th October 2020

Authors: Bulger E, May K, Robinson BR, Evans DC, Henry S, Green J et al.


The composite end point of this study included: alive at day 28; three or fewer debridements; no amputation; resolution of organ dysfunction. In this study that included 290 patients the composite endpoint was not improved by intervention (intention to treat), but organ dysfunction improved in patients who received the active drug.

Pubmed Link